Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 5 versus METHYLPREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 5 versus METHYLPREDNISOLONE ACETATE.
DEXONE 0.5 vs METHYLPREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist, binding to the glucocorticoid receptor (GR) and modulating gene expression through transactivation and transrepression. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, suppresses cytokine production (IL-1, IL-2, IL-6, TNF-alpha), and decreases immune cell migration and activation.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
0.5 mg orally once daily, with gradual taper to lowest effective dose
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
None Documented
None Documented
3.0-4.5 hours; prolonged in hepatic impairment (up to 6-8 hours) or concurrent CYP3A4 inhibitors
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
Renal: 70-80% (mostly as 6β-hydroxydexamethasone); biliary/fecal: 10-15%
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Category C
Category D/X
Corticosteroid
Corticosteroid